Exhibitors & Sponsors
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
BAG IT is committed to providing information to newly-diagnosed individuals with cancer and their families. This information helps educate, support and empower individuals to become active members of their treatment team.
BAG IT is designed to assist anyone with any type of cancer to Fight The Fear!
Science For A Better Life Bayer is one of the world's leading, innovative companies in the healthcare and medical products industry. In the US, our pharmaceuticals business is comprised of the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, Hematology/Neurology and Oncology. Our aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.
BriovaRx™ is a truly patient-centric specialty pharmacy, dedicated to making a meaningful impact on every patient’s well-being. We offer comprehensive, personalized specialty pharmacy care, including drug reimbursement verification and advocacy, confidential overnight delivery, patient education and emergency support for patients, competitive pricing, and access to many limited-distribution medications.
Color’s mission is to democratize access to genetic information. For $249, Color provides a clinical-grade physician ordered test. The Color Test analyzes 30-genes to help women and men learn their risk for the most common hereditary cancers: breast, ovarian, colorectal, pancreatic and other cancers. Complimentary genetic testing included.
Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, CA.
Helsinn is a privately owned pharmaceutical group headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the United States, and a representative office in China. Helsinn is one of the world’s leading supportive cancer care companies. Our portfolio of products combines therapies from those we license and those developed at Helsinn.
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems for therapeutic molecules that improve the quality of patients’ lives. Using proprietary sublingual spray technology and our capabilities to develop pharmaceutical cannabinoids, we work to address the clinical shortcomings of existing pharmaceutical products.
Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patient lives.
Tracking nodules has never been easier. LungDirect is Matrix Analytics’ software solution for pulmonary nodule and lung screening management. Through patient management and clinical outcomes, learning algorithms analyze big data to present real time clinical decision support. Matrix Analytics believes conquering disease requires data, creativity, and an unrelenting focus on Always Learning
Myriad Genetics is a leading molecular and companion diagnostics company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative products that assess a person’s risk of developing disease, aid in a timely and accurate diagnosis, determine the risk of disease progression and recurrence and guide personalized treatment decisions.
The mission of the NOCC is to save lives by fighting tirelessly to prevent and cure ovarian cancer, and to improve the quality of life for Survivors.
Our goals: to increase awareness about the symptoms, provide information to assist newly-diagnosed, hope to Survivors, and support to caregivers. We are also committed to the advancement of ovarian cancer research.
At Novartis, our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging health care issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Pfizer Oncology is committed to the discovery, investigation, and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time.
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine.
Sharsheret supports young Jewish women and families facing breast cancer at every stage―before, during, and after diagnosis. We provide educational resources, offer support to those at high risk of developing breast or ovarian cancer, and create programs for women and families to improve their quality of life.
Taiho Oncology has built a world-class clinical development organization that works urgently to develop innovative cancer treatments. Taiho is focused on bringing novel technology to cornerstone chemotherapies for a wide range of tumor types, including colorectal cancer and a variety of solid tumors.
Our mission is unchanged as we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation, and passion for improving the lives of patients. This singular focus drives our aspiration to discover, develop, and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.
We’ve built a portfolio of paradigm-changing therapies and a leading oncology pipeline. While we’ve made great strides in our fight against cancer, we are determined to do more—to work harder and to reach higher. We will do this with the same passion, agility, and entrepreneurial spirit that has sustained the heart of our culture and has made us the leader in oncology that we are today.
We know that our mission is not a quick or easy one, but we are up to the task: we aspire to cure cancer.